MONTREAL, QUEBEC--(Marketwire - July 21, 2008) - Ambrilia Biopharma Inc. (TSX: AMB) today announced that it has initiated the Phase I/II clinical development program of its proprietary, novel 3-month formulation of goserelin, in hormone-sensitive prostate cancer patients.
